These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 12090039)

  • 1. [Assessment of post-administration body distribution of toremifene and tamoxifen, and their administration regimens].
    Masuoka H; Mori M; Nomura N; Sakurai M; Yoshida K; Usuda N; Shirai H; Shimokawara I; Asaishi K
    Gan To Kagaku Ryoho; 2002 Jun; 29(6):881-7. PubMed ID: 12090039
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Results of phase II clinical trial of Tamoxifen and Toremifen in two different doses in advanced breast cancer in postmenopausal women].
    Gershanovich ML; Garin AM; Baltinia D; Kurvet A; Kangas L; Ellmen Iu
    Vopr Onkol; 1997; 43(6):587-95. PubMed ID: 9479357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients].
    Otsuka I; Takahashi S; O'uchi K; Akimoto N; Hanari K; Ogaki Y; Enatsu YH; Takigawa A; Takaya H; Tanaka A; Kaseki H; Yamada T
    Gan To Kagaku Ryoho; 2010 Feb; 37(2):279-83. PubMed ID: 20154485
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer.
    Kusama M; Miyauchi K; Aoyama H; Sano M; Kimura M; Mitsuyama S; Komaki K; Doihara H
    Breast Cancer Res Treat; 2004 Nov; 88(1):1-8. PubMed ID: 15538040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Plasma concentrations of toremifene citrate and N-desmethyltoremifene in postmenopausal patients with breast cancer--comparison of 120 mg of toremifene citrate administered once a day and divided into 3 separate doses (t.i.d.)].
    Shiba E; Watanabe T; Taguchi T; Tsukamoto F; Noguchi S
    Gan To Kagaku Ryoho; 2000 Feb; 27(2):245-9. PubMed ID: 10700895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of different combinations of tamoxifen and toremifene on estrogen receptor-positive breast cancer cell lines.
    Coradini D; Biffi A; Cappelletti V; Di Fronzo G
    Cancer Detect Prev; 1995; 19(4):348-54. PubMed ID: 7553677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Experience of high-dose toremifene treatment for postmenopausal women with metastatic breast cancer].
    Yamamoto Y; Kawazoe T; Iwase H
    Gan To Kagaku Ryoho; 2005 Oct; 32(10):1415-9. PubMed ID: 16227740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.
    Ingle JN; Suman VJ; Johnson PA; Krook JE; Mailliard JA; Wheeler RH; Loprinzi CL; Perez EA; Jordan VC; Dowsett M
    Clin Cancer Res; 1999 Jul; 5(7):1642-9. PubMed ID: 10430063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) administrations.
    Kusama M; Kaise H; Nakayama S; Ota D; Misaka T; Aoki T
    Breast Cancer Res Treat; 2004 Nov; 88(1):9-16. PubMed ID: 15538041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer--a comparative study by a double blind method with tamoxifen].
    Nomura Y; Tominaga T; Abe O; Izuo M; Ogawa N
    Gan To Kagaku Ryoho; 1993 Feb; 20(2):247-58. PubMed ID: 8434963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of high dose NK 622 (toremifene citrate) in tamoxifen failed patients with breast cancer].
    Asaishi K; Tominaga T; Abe O; Izuo M; Nomura Y
    Gan To Kagaku Ryoho; 1993 Jan; 20(1):91-9. PubMed ID: 8422190
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of chronic administration of mestranol, tamoxifen, and toremifene on hepatic ploidy in rats.
    Dragan YP; Shimel RJ; Bahnub N; Sattler G; Vaughan JR; Jordan VC; Pitot HC
    Toxicol Sci; 1998 Jun; 43(2):129-38. PubMed ID: 9710954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Combined effects of toremifene and paclitaxel on human breast cancer cell lines].
    Maruyama S; Kuroiwa S; Saimoto A; Nishikawa K
    Gan To Kagaku Ryoho; 2003 May; 30(5):669-75. PubMed ID: 12795099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Absence of DNA adduct in the leukocytes from breast cancer patients treated with toremifene.
    Umemoto A; Lin CX; Ueyama Y; Komaki K; Santosh Laxmi YR; Shibutani S
    Chem Res Toxicol; 2006 Mar; 19(3):421-5. PubMed ID: 16544947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary toremifene treatment for elderly postmenopausal women with breast cancer.
    Hamada N; Ogawa Y; Nishioka A; Kariya S; Yoshida S
    Oncol Rep; 2004 Feb; 11(2):365-70. PubMed ID: 14719069
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in bone mineral density during and after 3 years' use of tamoxifen or toremifene.
    Tiitinen A; Nikander E; Hietanen P; Metsä-Heikkilä M; Ylikorkala O
    Maturitas; 2004 Jul; 48(3):321-7. PubMed ID: 15207898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Efficacy and safety of high-dose toremifene for hormone-responsive advanced or metastatic breast cancer patients with failed prior treatment by aromatase inhibitors].
    Ohtake T; Yasuda M; Watanabe K; Ito T; Ito J; Miyamoto K; Yoshida S; Abe N; Ishigame T; Ishii M; Kimijima I; Takenoshita S
    Gan To Kagaku Ryoho; 2009 Sep; 36(9):1459-63. PubMed ID: 19755813
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
    Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
    J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
    Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
    Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.